Personalis Total Liabilities and Share Holders Equity 2018-2024 | PSNL

Personalis total liabilities and share holders equity from 2018 to 2024. Total liabilities and share holders equity can be defined as the total of all liabilities and shareholders' equity.
Personalis Annual Total Liabilities and Share Holders Equity
(Millions of US $)
2023 $225
2022 $293
2021 $397
2020 $245
2019 $157
2018 $42
2017 $0
Personalis Quarterly Total Liabilities and Share Holders Equity
(Millions of US $)
2024-09-30 $240
2024-06-30 $186
2024-03-31 $195
2023-12-31 $225
2023-09-30 $227
2023-06-30 $249
2023-03-31 $272
2022-12-31 $293
2022-09-30 $318
2022-06-30 $358
2022-03-31 $381
2021-12-31 $397
2021-09-30 $407
2021-06-30 $383
2021-03-31 $396
2020-12-31 $245
2020-09-30 $249
2020-06-30 $146
2020-03-31 $152
2019-12-31 $157
2019-09-30 $160
2019-06-30 $192
2019-03-31 $0
2018-12-31
2018-09-30 $0
2018-06-30 $0
2017-12-31 $0
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.239B $0.073B
Personalis Inc. is a cancer genomics company. It is engaged in the development of therapies by providing molecular data about each patient's cancer and immune response. Personalis Inc. is based in Menlo Park, California.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.350B 6.35
Dr Reddy's Laboratories (RDY) India $11.677B 22.35
BridgeBio Pharma (BBIO) United States $4.392B 0.00
Bausch Health Cos (BHC) Canada $3.009B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.142B 12.88
Supernus Pharmaceuticals (SUPN) United States $1.978B 26.93
Taysha Gene Therapies (TSHA) United States $0.447B 31.14
Assembly Biosciences (ASMB) United States $0.094B 0.00
Sol-Gel Technologies (SLGL) Israel $0.013B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00